Back to top
more

STERIS (STE)

(Real Time Quote from BATS)

$228.00 USD

228.00
8,333

-0.43 (-0.19%)

Updated Aug 5, 2025 09:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Steris (STE) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Steris (STE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 7.53% and 7.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

4 Stocks to Watch on Their Recent Dividend Hikes

by Zacks Equity Research

Investors may keep a tab on stocks like RCI, STE, AMP and CNI, which have lately hiked their dividend payments.

Zacks Equity Research

STERIS (STE) Set to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

Zacks Equity Research

STERIS (STE) Buys Surgical Instrumentation Platform From BDX

by Zacks Equity Research

STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.

Zacks Equity Research

Why Is Steris (STE) Down 0.9% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong segmental growth.

Zacks Equity Research

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Zacks Equity Research

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

by Zacks Equity Research

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Zacks Equity Research

Steris (STE) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 6.98% and 8.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 82.61% and 5.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

STERIS (STE) Set to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) fourth-quarter fiscal 2023 results are likely to reflect an impressive performance across the Healthcare and AST segments, with a gradual improvement in the supply chain.

Zacks Equity Research

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

by Zacks Equity Research

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

Zacks Equity Research

Steris (STE) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 18.89% and 9.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.

Zacks Equity Research

STERIS (STE) Gains on New Orders, FX Impact Dents Growth

by Zacks Equity Research

STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.

Zacks Equity Research

STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.

Zacks Equity Research

Steris (STE) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of -0.50% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.

Zacks Equity Research

Steris (STE) Down 0.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.